#Germany #Berlin #Cancer Research #Kelun-Biotech #ESMO

Overview of Kelun-Biotech's Upcoming Presentations at ESMO 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is set to participate in the prestigious 2025 European Society for Medical Oncology (ESMO) Congress, which will be held in Berlin, Germany, from October 17 to 21. This congress is a pivotal event for oncologists and researchers, gathering leading minds in oncology to discuss the latest breakthroughs and innovations in cancer treatments.

At this year's congress, Kelun-Biotech will present results from multiple clinical studies, showcasing their progress in developing targeted therapies that promise to enhance cancer treatment outcomes. One of the highlights will be the presentation of data concerning the company's well-regarded TROP2 antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), alongside findings from other clinical studies involving their HER2 and CLDN18.2 ADCs.

Featured Studies and Presentations

Among the key studies to be highlighted are:
1. Sacituzumab Tirumotecan (sac-TMT) vs. Platinum-based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
- Presentation Type: Presidential Symposium (LBA5)
- Date and Time: October 19, 4:52 PM - 5:04 PM local time
This study investigates the efficacy of sac-TMT in patients with EGFR-mutated NSCLC who have progressed after treatment with EGFR-TKIs. The implications of this research are significant, potentially offering a new treatment pathway for a challenging patient demographic.

2. Sacituzumab Tirumotecan (sac-TMT) in Breast Cancer
- Presentation Type: Proffered Paper (LBA23)
- Date and Time: October 18, 10:45 AM - 10:55 AM local time
This phase 3 study focuses on previously treated, locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, comparing sac-TMT to investigator's choice of chemotherapy.

3. HER2 ADC A166 vs. Trastuzumab Emersine (T-DM1) in HER2-positive Breast Cancer
- Presentation Type: Proffered Paper (LBA24)
- Date and Time: October 18, 10:55 AM - 11:05 AM local time
Findings from this randomized phase 3 study contribute substantially to our understanding of treatment transformations for HER2-positive conditions.

4. SKB315 and Other Investigational Therapies
- Additional posters will cover various studies, including novel antibody-drug conjugates targeting advanced solid tumors, with discussions scheduled for October 18 and 19 throughout the day.

Innovations in Cancer Treatment

Sacituzumab tirumotecan (sac-TMT) stands out as a cornerstone of Kelun-Biotech's current research, designed to specifically recognize TROP2 on tumor cells. Its unique mechanism includes the release of a cytotoxic agent, enhancing the focus on killing tumor cells while sparing healthy tissue. This ADC is framed within a broader strategy that includes various ongoing clinical trials aimed at improving outcomes for patients with advanced cancers.

The innovation doesn't stop there; the HER2 ADC, A166, is also gaining attention as it moves through the regulatory process for approval to treat advanced solid tumors. This drug signifies another leap forward in Kelun-Biotech's commitment to providing effective cancer treatments.

In summary, Kelun-Biotech's presence at the ESMO Congress marks a pivotal moment for the biopharmaceutical company and the oncology community, as they unveil critical research findings that have the potential to advance cancer treatment paradigms significantly. These presentations will undoubtedly draw considerable interest from medical professionals and researchers alike and could lead to new therapeutic options that address unmet needs for cancer patients worldwide.

For up-to-date information on the studies and further details on their implications, attendees are encouraged to visit the ESMO official webpage and engage with Kelun-Biotech representatives during the sessions.